Projected costs, risks, and benefits of expanded newborn screening for MCADD

Pediatrics

Volumn 125, Issue 2, 2010, Pages

  Prosser, Lisa A ^a,b   Kong, Chung Yin ^c   Rusinak, Donna ^b   Waisbren, Susan L ^d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cost effectiveness; Economic; Newborn screening; QALY

Indexed keywords

MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DIET THERAPY; ENZYME DEFICIENCY; FALSE POSITIVE RESULT; FOLLOW UP; HEALTH; HEALTH CARE COST; HEALTH HAZARD; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MEDICAL EXPERT; MONEY; NEWBORN; NEWBORN SCREENING; OUTCOME ASSESSMENT; PEDIATRICS; POPULATION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; UNITED STATES;

ACYL-COA DEHYDROGENASE; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; GENETIC TESTING; HUMANS; INFANT, NEWBORN; LIPID METABOLISM, INBORN ERRORS; NEONATAL SCREENING; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 76049103409     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-0605     Document Type: Article

References (46)

1. Kaye CI; American Academy of Pediatrics, Committee on Genetics. Introduction to the newborn screening fact sheets. Pediatrics. 2006;118(3):1304 -1312
2. Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr. 2002;141(4):524-531
3. Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001; 47(11):1945-1955
4. Tarini BA, Christakis DA, Welch HG. State newborn screening in the tandem mass spectrometry era: more tests, more falsepositive results. Pediatrics. 2006;118(2): 448-456
5. Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics. 2006;117(5):1793-1799
6. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a falsepositive result. Pediatrics. 2006;117(6): 1915-1921
7. Waisbren SE. Expanded newborn screening: information and resources for the family physician. Am Fam Physician. 2008;77(7): 987-994
8. Bilginsoy C, Waitzman N, Leonard CO, Ernst SL. Living with phenylketonuria: perspectives of patients and their families. J Inherit Metab Dis. 2005;28(5):639-649
9. Grosse SD. Cost-effectiveness as a criterion for newborn screening policy decisions: a critical review. In: Baily MA, Murray T, eds. Ethics and Newborn Genetic Screening: New Technologies, New Forces, New Challenges. Baltimore, MD: Johns Hopkins University Press; 2009:58-88
10. Grosse SD. Economic evaluations of newborn screening. In: Ungar WJ, ed. Economic Evaluation in Child Health. New York, NY: Oxford University Press; 2010:113-132
11. Norman R, Haas M, Wilcken B. International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy. 2009;89(3): 252-260
12. Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet. 2007;369(9555): 37- 42
13. Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilford BS. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics. 2006;117(3): 923-929
14. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003; 290(19):2564 -2572
15. Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003;111(6 pt 1):1399 -1406
16. Grosse SD, Khoury MJ, Greene CL, Crider KS. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med. 2006;8(4):205-212
17. Zimmerman H. Cost Analysis of the Rhode Island Newborn Screening Program. Providence, RI: Spectrum Research Services; 2004
18. Centers for Medicare and Medicaid Services. 2006 National Physician Fee Schedule Relative Value File: 2006. Available at www.cms.hhs.gov/ PhysicianFeeSched/ 01-overview.asp. Accessed August 4, 2009
19. Centers for Medicare and Medicaid Services. DRG relative weights: final version 22 (FY06 final notice data). Available at: www.cms.hhs.gov/ AcuteInpatientPPS/ 01-overview.asp. Accessed July 11, 2007
20. Prosser LA, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med. 2008;162(9):870-876
21. Statistics US Department of Labor, Bureau of Labor Statistics. National Compensation Survey: Occupational Earnings in the United States, June 2006. 2007. www.bls.gov/ncs/ ocs/sp/ncb10910.pdf. Accessed August 4, 2009
22. Honeycutt AA, Grosse SD, Dunlap LJ, et al. Economic costs of mental retardation, cerebral palsy, hearing loss, and vision impairment. In: Barnartt SN, Altman BM, eds. Using Survey Data to Study Disability: Results From the National Health Interview Survey on Disability. Oxford, United Kingdom: Elsevier Ltd; 2003:207-228
23. Chambers JG, Perez M, Socias M, Shkolnik J, Esra P, Brown SC. Educating Students With Disabilities: Comparing Methods for Explaining Expenditure Variation-Special Education Expenditure Project (SEEP). US Department of Education; 2004. www.csefair. org/publications/seep/national/ Rpt7.PDF. Accessed August 4, 2009
24. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. 2006. http://data.bls.gov/cgi-bin/surveymost. Accessed August 4, 2009
25. Prosser LA, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. PharmacoEconomics. 2007; 25(9):713-726
26. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000;21:587- 611
27. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
28. Lieu TA, McGuire TG, Hinman AR. Overcoming economic barriers to the optimal use of vaccines. Health Aff (Millwood). 2005;24(3): 666-679
29. Prosser LA, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics. 2004;113(2):283-290
30. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005;115(6):1675-1684
31. Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ. Cost-utility analyses of clinical preventive services: published ratios, 1976 -1997. Am J Prev Med. 2000;19(1): 15-23
32. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine. 2005;23(8): 1004 -1014
33. Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12(10):1548 -1558
34. Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for medium-chain acy1-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. 2003;112(5):1005-1015
35. Schoen EJ, Baker JC, Colby CJ, To TT. Costbenefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics. 2002;110(4):781-786
36. Pandor A, Eastham J, Chilcott J, Paisley S, Beverley C. Economics of tandem mass spectrometry screening of neonatal inherited disorders. Int J Technol Assess Health Care. 2006;22(3):321-326
37. Carroll AE, Downs SM. Comprehensive costutility analysis of newborn screening strategies. Pediatrics. 2006;117(5 pt 2):S287-S295
38. Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics. 2006; 117(5 pt 2):S280 -S286
39. Wilson JMG, Junger JJ. Principles and Practice of Screening for Disease. Geneva, Switzerland: World Health Organization; 1968
40. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler. 2003;9(3):311-319
41. Waisbren SE, Hanley W, Levy HL, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the maternal PKU collaborative study. JAMA. 2000; 283(6):756 -762
42. Kemper AR, Boyle CA, Aceves J, et al. Longterm follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet Med. 2008; 10(4):259 -261
43. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115(5). Available at: www.pediatrics.org/cgi/ content/full/115/ 5/e600
44. Petrou S, Gray R. Methodological challenges posed by economic evaluations of early childhood intervention programmes. Appl Health Econ Health Policy. 2005;4(3): 175-181
45. Petrou S. Methodological issues raised by preference-based approaches to measuring the health status of children. Health Econ. 2003;12(8):697-702
46. Keren R, Pati S, Feudtner C. The generation gap: differences between children and adults pertinent to economic evaluations of health interventions. PharmacoEconomics. 2004;22(2):71- 81